Search PubMed⌕ Search

Biomedical subjects

Robert C Bollinger

Publications and source records attributed to Robert C Bollinger.

22 records · Page 2Linked to original sources
PubMed2002

Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point.

T lymphocyte responses to human immunodeficiency virus (HIV) type 1 Gag were measured in 9 patients by interferon-gamma enzyme-linked immunospot assay at 3 time points within 12 months of infection. Patients with early recognition of HIV-1 Gag had lower subsequent HIV-1 load set points, as measured during the first 2 years of infection, compared with those of patients with undetectable Gag-specific responses (median, 4.27 vs. 5.05 log(10) HIV-1 RNA copies/mL, respectively; P=.028). An inverse correlation existed between the magnitude of the Gag-specific responses and the HIV-1 load set point (r=-0.733; P=.025). Early sustained T lymphocyte responses to HIV-1 Gag may be important for the establishment of virus load set point.

Adolescent↗
PubMed2002

Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays.

Identifying immunodominant regions of HIV-1 that are recognized by CD8(+) T lymphocytes in infected individuals may be important for the design and evaluation of candidate HIV-1 vaccines, particularly for developing countries. In this study, cryopreserved peripheral blood mononuclear cells (PBMCs) from 15 chronically HIV-1-infected U.S. volunteers were screened for HIV-1 Gag-specific T lymphocyte interferon gamma production in an enzyme-linked immunospot (ELISpot) assay matrix format, using overlapping HIV-1 subtype A, B, and C Gag peptide pools. In the initial matrix screen, responses to HIV-1 subtype B Gag were detected in 11 of 15 (73%) of seropositive individuals and in none of 4 HIV-1-seronegative controls. There were differences in both the breadth and magnitudes of the responses observed in the matrix assay. Responses varied in breadth, ranging from broad responses (more than four peptides) of moderate magnitude (<100 spot-forming cells [SFCs]/10(5) PBMCs) to narrowly focused (two or fewer peptides), more potent responses (>150 SFC/10(5) PBMCs). Responses to A, B, and C clade peptides of HIV-1 Gag revealed that all responders to subtype B peptides were also found to recognize corresponding peptides from at least one of the other clades. The ability to recognize cross-clade peptides with one or two amino acid substitutions relative to the B clade peptide was both peptide and patient dependent. Overall, our results show that the ELISpot matrix algorithm described here may be an efficient approach for characterizing cross-clade CD8(+) T cell responses in either seropositive individuals or in seronegative HIV-1 vaccine recipients.

AIDS Vaccines↗
PubMed2002

Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2 in the setting of multiple transmitted viral subtypes.

Rapid HIV testing is an appealing strategy in the approach to HIV diagnosis in developing countries. Concern has been raised about the use of these tests in the setting of multiple transmitted HIV subtypes. We sought to compare the OraQuick(TM) HIV-1/2 Test, a qualitative immunochromatographic test for the detection of antibodies to HIV-1 and HIV-2 using stored sera, with a conventional enzyme immunoassay (EIA)/Western blot (WB) algorithm. The study design used was a blinded retrospective study. Samples were collected on patients attending sexually transmitted disease clinics and tuberculosis clinics in Kinshasa, the Democratic Republic of Congo and included 72 known HIV seropositive and 131 known HIV seronegative subjects. All 72 known HIV seropositive samples were positive by OraQuick and all 131 known HIV seronegative samples were negative by OraQuick resulting in 100% sensitivity and specificity. We conclude that the OraQuick rapid HIV-1/2 test performs well in the setting of diverse HIV viral subtypes.

AIDS Serodiagnosis↗